Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV

Virology

Volumn 410, Issue 1, 2011, Pages 76-87

  McGregor, A ^a   Choi, K Y ^a   Schleiss, M R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antiviral; Bacterial artificial chromosome (BAC); Chimera; Congenital infection; Cytomegalovirus; Guinea pig; Homolog; Pp65; Transdominant inhibition; UL84

Indexed keywords

PROTEIN GP84; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; VIROGENESIS; VIRUS GENE; VIRUS INHIBITION;

ANIMALS; CELL LINE; CYTOMEGALOVIRUS; GENE DELETION; GENE EXPRESSION REGULATION, VIRAL; GENETIC COMPLEMENTATION TEST; GUINEA PIGS; HUMANS; REASSORTANT VIRUSES; ROSEOLOVIRUS; VIRAL PROTEINS;

BACTERIA (MICROORGANISMS); CAVIA; CYTOMEGALOVIRUS; GUINEA PIG CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 78650729551     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.10.028     Document Type: Article

References (51)

1. Abate D.A., Watanabe S., Mocarski E.S. Major human cytomegalovirus structural protein pp 65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 2004, 78:10995-11006.
2. Baldick C.J., Marchini A., Patterson C.E., Shenk T. Human cytomegalovirus tegument protein pp 71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J. Virol. 1997, 71:4400-4408.
3. Barry P.A., Lockridge K.M., Salamat S., Tinling S.P., Yue Y., Zhou S.S., Gospe S.M., Britt W.J., Tarantal A.F. Non-human primate models of intrauterine cytomegalovirus infection. ILAR J. 2006, 47:49-64.
4. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 71:154-163.
5. Cantrell S.R., Bresnahan W.A. Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication. J. Virol. 2006, 80:6188-6191.
6. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008, 18:233-246.
7. Colletti K.S., Xu Y., Cei S.A., Tarrant M., Pari G.S. Human cytomegalovirus UL84 oligomerization and heterodimerization domains act as transdominant inhibitors of oriLyt-dependent DNA replication: evidence that IE2-UL84 and UL84-UL84 interactions are required for lytic DNA replication. J. Virol. 2004, 78:9203-9214.
8. Colletti K.S., Xu Y., Yamboliev I., Pari G.S. Human cytomegalovirus UL84 is a phosphoprotein that exhibits UTPase activity and is a putative member of the DExD/H box family of proteins. J. Biol. Chem. 2005, 280:11955-11960.
9. Davison A.J., Stow N.D. New genes from old: redeployment of dUTPase by herpesviruses. J. Virol. 2005, 79:12880-12892.
10. Dunn W., Chou C., Li H., Hai R., Patterson D., Stolc V., Zhu H., Liu F. Functional profiling of a human cytomegalovirus genome. Proceedings of the National Academy of Science, USA 2003, 100:14223-14228.
11. Gao M., Isom H.C. Characterization of the guinea pig cytomegalovirus genome by molecular cloning and physical mapping. J. Virol. 1984, 52:436-447.
12. Gebert S., Schmolke S., Sorg G., Floss S., Plachter B., Stamminger T. The UL84 protein of human cytomegalovirus acts as a transdominant inhibitor of immediate-early-mediated transactivation that is able to prevent viral replication. J. Virol. 1997, 71:7048-7060.
13. Gonczol E., Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin. Biol. Ther. 2001, 1:401-412.
14. Griffiths P.D., Walter S. Cytomegalovirus. Curr. Opin. Infect. Dis. 2005, 18:241-245.
15. Hahn G., Rose D., Wagner M., Rhiel S., McVoy M.A. Cloning of the genomes of human cytomegalovirus strains Toledo, TownevarRIT3, and Towne long as BACs and site-directed mutagenesis using a PCR-based technique. Virology 2003, 307:164-177.
16. He Y.S., Xu L., Huang E.S. Characterization of human cytomegalovirus UL84 early gene and identification of its putative protein product. J. Virol. 1992, 66:1098-1108.
17. Hensel G.M., Meyer H.H., Buchmann I., Pommerehne D., Schmolke S., Plachter B., Radsak K., Kern H.F. Intracellular localization and expression of the human cytomegalovirus matrix phosphoprotein pp 71 (ppUL82): evidence for its translocation into the nucleus. J. Gen. Virol. 1992, 77:3087-3097.
18. Holtappels R., Podlech J., Grzimek N.K., Thomas D., Pahl-Seibert M.F., Reddehase M.J. Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). Virology 2001, 75:6584-6600.
19. Kaiser N., Lischka P., Wagenknecht N., Stamminger T. Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84. J. Virol. 2009, 83:11902-11913.
20. Kumar M.L., Nankervis G.A. Experimental congenital infection with cytomegalovirus: a guinea pig model. J. Infect. Dis. 1978, 138:650-654.
21. Kern E.R. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res. 2006, 71:164-171.
22. Lischka P., Sorg G., Kann M., Winkler M., Stamminger T. A non-conventional nuclear localization signal within the UL84 protein of human cytomegalovirus mediates nuclear import via the importin alpha/beta pathway. J. Virol. 2003, 77:3734-3748.
23. Lischka P., Rauh C., Mueller R., Stamminger T. Human cytomegalovirus UL84 protein contains two nuclear export signals and shuttles between the nucleus and the cytoplasm. J. Virol. 2006, 80:10274-10280.
24. Loregian A., Marsden H.S., Palù G. Protein-protein interactions as targets for antiviral chemotherapy. Rev. Med. Virol. 2005, 12:239-262.
25. McGregor A., Schleiss M.R. Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. Mol. Genet. Metab. 2001, 72:15-26.
26. McGregor A., et al. Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp 71 (UL82) and pp65 (UL83). J. Virol. 2004, 78:9872-9889.
27. McGregor A. Current or new cytomegalovirus antivirals and novel animal model strategies. Inflamm. Allergy Drug Targets 2010, 9:286-299.
28. McGregor A., Choi K.Y., Cui X., McVoy M.A., Schleiss M.R. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir. Antiviral Res. 2008, 78:250-259.
29. McGregor A., Liebelt J., Bouska C., Schleiss M. A chimeric guinea pig cytomegalovirus (GPCMV) encoding wild type or mutant HCMV UL97 renders GPCMV susceptible or resistant to ganciclovir while retaining an ability to disseminate in the animal host. Antiviral Res. 2010, 86:A23, 26.
30. Morello C.S., Cranmer L.D., Spector D.H. In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83). J. Virol. 1999, 73:7678-7693.
31. Morello C.S., Cranmer L.D., Spector D.H. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp 65). J. Virol. 2000, 74:3696-3708.
32. Pass R.F. Cytomegalovirus. Fields Virology 2001, vol. 2:2675-2705. Williams & Wilkins, Philadelphia: Lippincott. 4th ed. D.M. Knipe (Ed.).
33. Reid G.G., Ellsmore V., Stow N.D. An analysis of the requirements for human cytomegalovirus oriLyt-dependent DNA synthesis in the presence of the herpes simplex virus type 1 replication fork proteins. Virology 2003, 308:303-316.
34. Robinson J.A., Demarco S., Gombert F., Moehle K., Obrecht D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today. 2008, 13:944-951.
35. Ross S.A., Boppana S.B. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis. 2005, 16:44-49.
36. Sarisky R.T., Hayward G.S. Evidence that the UL84 gene product of human cytomegalovirus is essential for promoting oriLyt-dependent DNA replication and formation of replication compartments in co-transfection assays. J. Virol. 1996, 70:7398-7413.
37. Schleiss M.R., McGregor A., Jensen N.J., Erdem G., Aktan L. Molecular characterization of the guinea pig cytomegalovirus UL83 (pp65) protein homolog. Virus Genes 1999, 19:205-221.
38. Schleiss M.R. Sequence and transcriptional analysis of the guinea-pig cytomegalovirus DNA polymerase gene. J Gen Virol. 1995, 76(Pt 7):1827-1833.
39. Schleiss M.R. Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J Clin Virol. 2002, 25:S37-S49.
40. Schleiss M.R. Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J. 2006, 47:65-72.
41. Schleiss M.R., Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev. Vaccines 2006, 4:381-406.
42. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., Alterson K., Chulay J.D., Smith J.F. Pre-conceptual administration of an alphavirus replicon UL83 (pp 65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 2007, 195:789-798.
43. Schleiss M.R., McGregor A., Choi K.Y., Date S.V., Cui X., McVoy M.A. Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol J. 2008, 5:139.
44. Schmolke S., Kern H.F., Drescher P., Jahn G., Plachter B. The dominant phosphoprotein pp 65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J. Virol. 1995, 69:5959-5968.
45. Strang B.L., Sinigalia E., Silva L.A., Coen D.M., Loregian A. Analysis of the association of the human cytomegalovirus DNA polymerase subunit UL44 with the viral DNA replication factor UL84. J. Virol. 2009, 83:7581-7589.
46. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., Sissons J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp 65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 1996, 70:7569-7579.
47. Xu Y., Colletti K.S., Pari G.S. Human cytomegalovirus UL84 localizes to the cell nucleus via a nuclear localization signal and is a component of viral replication compartments. J. Virol. 2002, 76:8931-8938.
48. Xu Y., Cei S.A., Huete A.R., Pari G.S. Human cytomegalovirus UL84 insertion mutant defective for viral DNA synthesis and growth. J. Virol. 2004, 78:10360-10369.
49. Yamada S., Nozawa N., Katano H., Fukui Y., Tsuda M., Tsutsui Y., Kurane I., Inoue N. Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 2009, 391:99-106.
50. Ye M., Morello C.S., Spector D.H. Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization. J. Virol. 2004, 78:11233-11245.
51. Yu D., Silva M.C., Shenk T. Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proceedings of the National Academy of Sciences, USA 2003, 100:12396-12401.